ZMYM2-FGFR1 fusion as secondary change in acute myeloid leukemia
暂无分享,去创建一个
[1] S. Verstovsek,et al. Treatment of the myeloid/lymphoid neoplasm with FGFR1 rearrangement with FGFR1 inhibitor. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[2] V. Najfeld,et al. Myeloid/lymphoid neoplasms with FGFR1 rearrangement , 2018, Leukemia & lymphoma.
[3] Massimo Cristofanilli,et al. Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application , 2016, Oncotarget.
[4] W. Hofmann,et al. Limited Efficacy of Ponatinib in Myeloproliferative Neoplasms Associated with FGFR1 Fusion Genes , 2015 .
[5] Razelle Kurzrock,et al. The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing , 2015, Clinical Cancer Research.
[6] P. Koduru,et al. Myeloid and lymphoid neoplasm with abnormalities of FGFR1 presenting with trilineage blasts and RUNX1 rearrangement: a case report and review of literature. , 2015, American journal of clinical pathology.
[7] K. Döhner,et al. Mutational spectrum of myeloid malignancies with inv(3)/t(3;3) reveals a predominant involvement of RAS/RTK signaling pathways. , 2015, Blood.
[8] S. Baruchel,et al. Late‐appearing Philadelphia chromosome in childhood acute myeloid leukemia , 2008, Pediatric blood & cancer.
[9] H. Kantarjian,et al. Association of 3q21q26 syndrome and late-appearing Philadelphia chromosome in acute myeloid leukemia , 2008, Leukemia.
[10] K. Theil,et al. The Philadelphia chromosome as a secondary abnormality in inv(3)(q21q26) acute myeloid leukemia at diagnosis: confirmation of p190 BCR-ABL mRNA by real-time quantitative polymerase chain reaction. , 2006, Cancer genetics and cytogenetics.
[11] D. Fabbro,et al. PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[12] A. Reiter,et al. The 8p11 Myeloproliferative Syndrome: A Distinct Clinical Entity Caused by Constitutive Activation of FGFR1 , 2002, Acta Haematologica.
[13] A. Levis,et al. A fourth case of BCR-FGFR1 positive CML-like disease with t(8;22) translocation showing an extensive deletion on the derivative chromosome 8p. , 2002, The hematology journal : the official journal of the European Haematology Association.
[14] J. Aster,et al. ZNF198-FGFR1 transforming activity depends on a novel proline-rich ZNF198 oligomerization domain. , 2000, Blood.
[15] H. Drexler,et al. Recent results on the biology of Hodgkin and Reed-Sternberg cells. II. Continuous cell lines. , 1993, Leukemia & lymphoma.